Short answer
ImmunityBio, Inc. (IBRX) filed an 8-K current report with the SEC on February 23, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q4 and full-year 2025 financial results released Feb 23, 2026; details in Exhibit 99.1.
ImmunityBio, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q4 and full-year 2025 financial results released Feb 23, 2026; details in Exhibit 99.1
- Filing covers period ending Dec 31, 2025, including balance sheet position as of that date
- Results accompanied by a "business update," signaling potential operational developments beyond routine financials
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ImmunityBio, Inc. 8-K filings
Get the next IBRX 8-K as it lands
Follow IBRX for push alerts, or ask the research agent what this filing means.